$AVRO News

Last published 2y ago

2y agoAVROTectonic Therapeutic Appoints Daniel Lochner as Chief Financial OfficerBusiness WireTectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief
2y agoAVROTectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart FailureBusiness WireStudy to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on
2y agoCHRD AVRO KAMN CTLTKuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoAVROTectonic Therapeutic Announces Participation at Investor Conferences in MarchBusiness WireTectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of
2y agoICVX CSTR AVRO CALBKuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoAVROAVROBIO and Tectonic Therapeutic Announce MergerBusiness WireCombined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic's novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and
3y agoAVROAVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 MillionBusiness WireAll-cash transaction, full $87.5 million paid at closing Proceeds expected to extend cash runway into Q4 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a
3y agoAVROAVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 MillionBusiness WireAll-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free
3y agoAVROAVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual MeetingBusiness WireAll patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable reduction in leukocyte cystine levels across all patients Received positive regulatory feedback from US and
3y agoAVROAVROBIO Reports First Quarter 2023 Financial Results and Provides Business UpdateBusiness WireOn track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis
3y agoAVROAVROBIO Announces Leadership TransitionBusiness WireCurrent CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of
3y agoAVROAVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdateBusiness WireFollowing positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in
3y agoAVROAVROBIO to Participate in Cowen's 43rd Annual Health Care ConferenceBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to
3y agoAVROAVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023Business WireFour platform presentations and two posters with data on AVROBIO's lysosomal disorder programs to be presented AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a
3y agoAVROAVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock
3y agoAVROAVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene TherapyBusiness WireNew compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3 patient, the more
3y agoAVROAVROBIO to Share Comprehensive Gaucher Disease Program UpdateBusiness WireWebcast on Wednesday, Dec. 7, 2022, at 8 am ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a
4y agoAVROAVROBIO Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness WirePatient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies Comprehensive
4y agoAVROAVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy SummitBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled
4y agoAVROAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 13,000 restricted stock
4y agoAVROAVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher DiseaseBusiness WireAVR-RD-02 has previously received Fast Track status from FDA, orphan drug designation in the U.S. and EU, and ILAP designation from the U.K. MHRA AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene
4y agoAVROAVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for CystinosisBusiness WireFirst five patients in Phase 1/2 trial show systemic gene therapy effect across multiple tissues evaluated, including eyes, skin, gastrointestinal mucosa and neurocognitive system AVROBIO planning to initiate
4y agoAVROAVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher DiseaseBusiness WireILAP intended to accelerate regulatory review process and facilitate patient access in U.K. for seriously debilitating and life-threatening diseases AVR-RD-02 has previously received Fast Track status from U.S. FDA and
4y agoAVROAVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical DevelopmentBusiness WireAVROBIO leading industry in combining use of two safety assays to evaluate genotoxicity risk prior to moving into clinical trials New safety assay uses machine learning algorithms and transcriptional profile data
4y agoAVROAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 28,000 restricted stock units (RSUs) to two new employees
4y agoAVROAVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual CongressBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector safety at
4y agoAVROAVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for CystinosisBusiness WireSecond AVROBIO gene therapy program that has been granted rare pediatric disease designation by FDA AVR-RD-04 has previously received orphan drug designation from FDA and EMA AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy compa
4y agoAVROAVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy TrialBusiness WireFirst in-human pediatric Phase 1/2 study to evaluate the safety and tolerability of first-in-class gene therapy targeting infants age ≥3 months and ≤12 months, diagnosed with nMPS-II University of Manchester (U.K.) expects to initiate clinical tr
4y agoAVROAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 58,000 restricted stock units (RSUs) to three new employee
4y agoAVROAVROBIO to Participate in Four Upcoming Investor Conferences in SeptemberBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming investor confe
4y agoAVROAVROBIO Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness WirePresented positive data from first five patients in Phase 1/2 cystinosis trial1 showing systemic gene therapy effect at the American Society of Gene and Cell Therapy Annual Meeting; all five patients remain off oral cysteamine Comprehensive Gaucher d
4y agoAVROAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 35,500 restricted stock units (RSUs) to thre
4y agoAVROAVROBIO to Participate in Two Upcoming Investor Conferences in AugustBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming i
4y agoAVROAVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter SyndromeBusiness WireAVR-RD-05 is the fourth AVROBIO gene therapy to receive orphan drug designation FDA previously granted rare pediatric disease designation for AVR-RD-05 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpos
4y agoAVROAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 37,500 restricted stock units (RSUs) to thre
4y agoAVROAVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual MeetingBusiness WireGenetically modified hematopoietic stem cells lead to supraphysiological levels of therapeutic protein in a mouse model of Pompe disease sustained at eight months after administration Substantial reduction in glycogen observed across cardiac and skel
4y agoAVROAVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive MeasuresBusiness WireNew early data show key visual motor integration, visual perception and motor coordination measures impacted by cystinosis stabilized or improved post gene therapy Systemic reach of AVR-RD-04 observed across multiple other measures All five dosed
4y agoAVROAVROBIO to Present at the H.C. Wainwright Global Investment ConferenceBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced members of its senior management team will be presenting virtually at the H.C. Wainwright
4y agoAVROAVROBIO Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness WirePhase 1/2 collaborator-sponsored1 clinical trial in cystinosis fully enrolled New interim cystinosis clinical data to be presented at the 25th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) Multiple regulatory interactions
4y agoAVROAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,00
4y agoAVROAVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual MeetingBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that new data from its ongoing, collaborator-sponsored1 Phase 1/2 clinical trial in cysti
4y agoAVROAVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 22,000 share
4y agoAVROAVROBIO to Present at the 21st Annual Needham Virtual Healthcare ConferenceBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the 21st Annual Needham Virtu
4y agoAVROAVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business UpdateBusiness WireProvided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update o
4y agoAVROAVROBIO to Present at Two Upcoming Investor Conferences in MarchBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming i
4y agoAVROAVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for CystinosisBusiness WireSustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patien
4y agoAVROAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an agg
4y agoAVROAVROBIO Announces the Appointment of Sean O'Bryan as Chief Regulatory OfficerBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O'Bryan as chief regulatory officer. Sean brings a wealth of expe
4y agoAVROAVROBIO to Present at Cowen's 2nd Annual Genetic Medicines SummitBusiness WireAVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Co
4y agoAVROAVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022Business WireAnalyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company's clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposiu